agenT-797 for Solid Tumors

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: MiNK Therapeutics

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a new immune cell therapy called agenT-797 in patients whose solid tumors have come back or didn't respond to other treatments. The therapy uses special immune cells from a donor to help the patient's body fight the cancer.

Research Team

Medical Director

Principal Investigator

MiNK Therapeutics

Eligibility Criteria

Inclusion Criteria

Measurable disease per RECIST 1.1 as assessed by local site Investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions

Histological or cytological evidence of relapsed or refractory solid tumor malignancy for which no standard therapy is available or standard therapy has failed

Part 2 only, participants must have progressed per Investigator assessment on pembrolizumab or nivolumab, and agree and are able to continue on the inhibitor(s) while on study

See 1 more

Exclusion Criteria

You have another type of cancer at the same time.

You have cancer that has spread to your brain or the covering of your brain and it is either not being treated or is currently being treated.

Prior radiotherapy within 2 weeks of start of study treatment

Treatment Details

Interventions

agenT-797 (CAR T-cell Therapy)
Approved anti-PD-1 (Checkpoint Inhibitor)
Approved ICIs (Checkpoint Inhibitor)

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Part 2: agenT-797 in Combination with approved ICIsExperimental Treatment2 Interventions

Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care

Group II: Part 1: Monotherapy with agenT-797Experimental Treatment1 Intervention

3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.